Teva Pharmaceuticals (Spain)

Recent papers from Teva Pharmaceuticals (Spain)

1. Assessment of Dose Proportionality and the Effect of Food on a Once-Daily Extended-Release Tablet Formulation of Deutetrabenazine in Healthy ParticipantsClinical Drug Investigation · 2026
2. Practical Multi-Task Learning for Rare Conversions in Ad Tech2025
3. EBV BALF2 DNA annealing intermediate structure reveals the mechanism of annealing during recombination2025
4. MOSPD2 regulates the activation state of αLβ2 integrin to control monocyte migration: applicability for treatment of chronic inflammatory diseasesImmunologic Research · 2025
5. Crosstalk between bone metastatic cancer cells and sensory nerves in bone metastatic progressionLife Science Alliance · 2024
6. Measurement and Modeling of Peripherally Administered Anti-CGRP Monoclonal Antibody in CSF and Brain of Healthy Volunteers (S22.006)Neurology · 2024
7. A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady StateClinical Pharmacology in Drug Development · 2024
8. Incidence of Adverse Events Associated With Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated With Huntington’s Disease (4416)Neurology · 2021
9. Defining Utility Values for Chorea Health States in Patients With Huntington’s Disease (4360)Neurology · 2021
10. Lumican regulates cervical corticospinal axon collateralization via non-autonomous crosstalk between distinct corticospinal neuron subpopulations2021
11. Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease (4310)Neurology · 2020
12. Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia (2003)Neurology · 2020
13. Very Early Onset of Action of Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medications: Results of the International, Multicenter, Randomized, Placebo-controlled FOCUS Study (4371)Neurology · 2020
14. Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluationRegulatory Toxicology and Pharmacology · 2020
15. Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPDEuropean Clinical Respiratory Journal · 2020
16. Central nervous system effects of the histamine‐3 receptor antagonist CEP‐26401, in comparison with modafinil and donepezil, after a single dose in a cross‐over study in healthy volunteersBritish Journal of Clinical Pharmacology · 2019
17. Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approachScientific Reports · 2019
18. Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjectsBasic & Clinical Pharmacology & Toxicology · 2018
19. Inspiring process innovation via an improved green manufacturing metric: iGALGreen Chemistry · 2018
20. Synaptopodin is upregulated by IL-13 in eosinophilic esophagitis and regulates esophageal epithelial cell motility and barrier integrityJCI Insight · 2017